Key result
EuroSCORE II demonstrated lower discriminative and predictive efficacy for in-hospital mortality among Egyptian patients undergoing valvular surgery, with an overall observed mortality rate of 7.8%.
Why the study?
EuroSCORE II was validated to predict in-hospital mortality after cardiac surgery, but its accuracy in Egyptian patients undergoing valve surgery needed evaluation.
Does EuroSCORE II accurately predict in-hospital mortality in Egyptian patients undergoing valvular surgery?
Cohort (n=180)
Yes
Does EuroSCORE II accurately predict in-hospital mortality in Egyptian patients undergoing valvular surgery?
EuroSCORE II demonstrated lower discriminative and predictive efficacy in Egyptian patients undergoing valvular surgery, suggesting the need for adjustments based on local risk factors.
Clinicians should use EuroSCORE II cautiously in Egyptian valvular surgery patients; leaves open validation of locally calibrated models.
Background: Models have been developed to predict a variety of outcomes, for all cardiac surgery and also for specific cardiac surgery procedures. The most broadly utilized model for anticipating mortality in cardiovascular surgery was EuroSCORE I, which has been upgraded in recent times to EuroSCORE II which was validated as a predictor for in-hospital mortality after cardiac surgery. Objective: The aim of the present study was to evaluate the accuracy of EuroSCORE II in prediction of mortality in Egyptian patients who would undergo valve surgery. Patients and methods: This retrospective cohort study evaluated the medical records of 180 adult patients who underwent valvular surgery in Departments of Cardiothoracic Surgery at Zagazig University Hospitals and Cardiac Surgery at National Heart Institute in Egypt, between January 2021 and July 2021. All studied patients were subjected to careful history taking, general examination, local cardiac examination, laboratory investigation, electrocardiogram, body mass index, and echocardiography. Results: The most common procedure done was mitral valve replacement representing (33.9%) followed by combined mitral valve replacement and tricuspid valve repair. The observed rate of in-hospital mortality was 7.8% (n = 14 patients). The real observed mortality rate was 4.4% of patients in 1st quartile, 10.9% in 2nd quartile, 14.6% of 3rd quartile and 0.0% in 4th quartile, with significant difference. Conclusion: The lower discriminative and predictive efficacy of EuroSCORE II in Egyptian patients undergoing mitral valve replacement might be explained by differences in clinical profile and the existence of additional local risk factors.
No takes yet. Share an insight, caveat, or question.
Elnahal et al. (2022) conducted a cohort in Valvular surgery (n=180). EuroSCORE II was evaluated on In-hospital mortality. EuroSCORE II demonstrated lower discriminative and predictive efficacy for in-hospital mortality among Egyptian patients undergoing valvular surgery, with an overall observed mortality rate of 7.8%.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: